Today’s Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / The markets weren’t really what you would call bullish yesterday. Barring a few, most of the stocks seeing changes of as little as 0.2-0.5%, either in the green or the red. That pretty much summed up Dow Jones and NASDAQ as well, which closed just 0.20% down and 0.38% up respectively. The only major news that came in through the day was that Ford has decided to recall as many as 441,000 vehicles.

RDI Initiates Coverage:

Catalyst Biosciences
Inc. https://ub.rdinvesting.com/news/?ticker=CBIO

Pernix Therapeutics
Holdings Inc. https://ub.rdinvesting.com/news/?ticker=PTX

Catalyst Biosciences Inc. didn’t really have a great day. On an otherwise normal day, the stock managed to lose as much as 29.98%. It opened at around $17.80 near touched the high of $18.10 but by the end of the day, the stock fell to $10.51. The company last month completed a reverse stock split of one-for-fifteen, after its shares fell to a value of $4.73. The company’s shares traded at around $24.90 a year back on March 30, 2016. After the reverse split, it rose above $15 but has again fallen to the $10 mark.

On March 28th, the company announced that CB 2679d/ISU304, a highly potent next-generation coagulation Factor IX variant, has received the Investigational New Drug Application (IND) approval from the Korean Ministry of Food and Drug Safety (MFDS).

Access RDI’s Catalyst Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=CBIO

Pernix Therapeutics shares fell 13.05% to close at $3.53 a share. The stock traded in a range of $3.08 to $3.67 a share on volume of 643,700 shares traded. Last December, the shares fell to a record low of $1.94, which was just above the $1 bid price that the company needed to be eligible to be listed on the NASDAQ stock exchange. It seems that the 42% gains the company made in share prices after winning its patent case against generic from Actavis Labs is being wiped out. It remains to be seen whether the downward trend will continue further or we have reached the threshold point.

Access RDI’s Pernix Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=PTX

Our Actionable Research on Catalyst Biosciences Inc. (NASDAQ: CBIO) and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458547